(Q41454232)

30 September 2017

1 reference

title

Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias (English)

1 reference

30 September 2017

1 reference

Lea AP

1

1 reference

PubMed ID

9129869

30 September 2017

McTavish D

series ordinal

2

1 reference

30 September 2017

1 May 1997

1 reference

30 September 2017

1 reference

30 September 2017

53

1 reference

30 September 2017

828-847

1 reference

30 September 2017

5

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199753050-00011

30 September 2017

0 references

cites work

Developmental toxicity of the HMG-CoA reductase inhibitor, atorvastatin, in rats and rabbits.

1 reference

12 December 2020

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects

1 reference

12 December 2020

Pathogenesis and management of lipoprotein disorders

1 reference

12 December 2020

Management of primary hyperlipidemia

1 reference

12 December 2020

Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.

1 reference

12 December 2020

Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease

1 reference

12 December 2020

The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study

1 reference

12 December 2020

Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension

1 reference

12 December 2020

Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin

1 reference

12 December 2020

Comparative effects of HMG-CoA reductase inhibitors on apo B production in the casein-fed rabbit: atorvastatin versus lovastatin

1 reference

12 December 2020

A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events).

1 reference

12 December 2020

Role of cholesterol in regulating apolipoprotein B secretion by the liver

1 reference

12 December 2020

Mechanisms of triglyceride-lowering effect of an HMG-CoA reductase inhibitor in a hypertriglyceridemic animal model, the Zucker obese rat

1 reference

12 December 2020

Regression growth evaluation statin study (REGRESS): study design and baseline characteristics in 600 patients. The REGRESS Research Group

1 reference

12 December 2020

Clinical pharmacokinetics and practical applications of simvastatin

1 reference

12 December 2020

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia

1 reference

12 December 2020

Plasma mevalonate as a measure of cholesterol synthesis in man

1 reference

12 December 2020

Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate.

1 reference

12 December 2020

Risk factors for myocardial infarction in the Stockholm prospective study. A 14-year follow-up focussing on the role of plasma triglycerides and cholesterol

1 reference

12 December 2020

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

12 December 2020

The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981

1 reference

12 December 2020

Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation

1 reference

12 December 2020

Simvastatin but not pravastatin has a direct inhibitory effect on rat and human myocyte proliferation

1 reference

12 December 2020

Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program

1 reference

12 December 2020

The genotoxicity profile of atorvastatin, a new drug in the treatment of hypercholesterolemia.

1 reference

12 December 2020

Change in cholesterol awareness and action. Results from national physician and public surveys

1 reference

12 December 2020

Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits

1 reference

12 December 2020

Fertility and general reproduction studies in rats with the HMG-CoA reductase inhibitor, atorvastatin

1 reference

12 December 2020

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

1 reference

12 December 2020

1 reference

12 December 2020

Physiological disposition of HMG-CoA-reductase inhibitors

1 reference

12 December 2020

Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study

1 reference

12 December 2020

Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications

1 reference

12 December 2020

Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.

1 reference

12 December 2020

Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial

1 reference

12 December 2020

Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men

1 reference

12 December 2020

A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients witb hypercholesterolemia

1 reference

12 December 2020

Effects of free fatty acids on activity of hepatic microsomal 3-hydroxy-3-methylglutaryl coenzyme A reductase and on secretion of triglyceride and cholesterol by liver

1 reference

12 December 2020

Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group

1 reference

12 December 2020

Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia

1 reference

12 December 2020

Is vascular smooth muscle cell proliferation beneficial?

1 reference

12 December 2020

Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig.

1 reference

12 December 2020

The 4S study. Implications for prescribing

1 reference

12 December 2020

West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials

1 reference

12 December 2020

Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease

1 reference

12 December 2020

The triglyceride issue revisited. Findings from the Helsinki Heart Study.

1 reference

12 December 2020

The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day

1 reference

12 December 2020

Epidemiology of hypercholesterolemia and European management guidelines

1 reference

12 December 2020

Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I).

1 reference

12 December 2020

Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries.

1 reference

12 December 2020

Direct correlation between cholesterol synthesis and hepatic secretion of apolipoprotein B-100 in normolipidemic subjects

1 reference

12 December 2020

A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction

1 reference

12 December 2020

Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models.

1 reference

12 December 2020

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

1 reference

12 December 2020

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

1 reference

12 December 2020

Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)

1 reference

12 December 2020

Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia

1 reference

12 December 2020

Plasma triglyceride and coronary heart disease

1 reference

12 December 2020

Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.

1 reference

12 December 2020

Plasma triglyceride level and mortality from coronary heart disease

1 reference

12 December 2020

Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia

1 reference

12 December 2020

Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase

1 reference

12 December 2020

Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase

1 reference

12 December 2020

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts

1 reference

12 December 2020

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)

1 reference

12 December 2020

Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: Comparison with selected HMG-CoA reductase inhibitors

1 reference

12 December 2020

A review of clinical trials comparing HMG-CoA reductase inhibitors

1 reference

12 December 2020

Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor.

1 reference

12 December 2020

Regulation of apoB secretion from HepG2 cells: evidence for a critical role for cholesteryl ester synthesis in the response to a fatty acid challenge

1 reference

12 December 2020

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering

1 reference

12 December 2020

Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia

1 reference

12 December 2020

On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors

1 reference

12 December 2020

Statins do more than just lower cholesterol

1 reference

12 December 2020

Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study

1 reference

12 December 2020

Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

12 December 2020

Subchronic toxicity of atorvastatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor, in beagle dogs.

1 reference

12 December 2020

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)

1 reference

12 December 2020

Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation

1 reference

12 December 2020

Effect of age and gender on pharmacokinetics of atorvastatin in humans.

1 reference

12 December 2020

Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease

1 reference

12 December 2020

Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension

1 reference

12 December 2020

The triglyceride issue: a view from Framingham

1 reference

12 December 2020

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

1 reference

12 December 2020

Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study

1 reference

12 December 2020

Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association

1 reference

12 December 2020

10.2165/00003495-199753050-00011

Identifiers

DOI

1 reference

PubMed ID

9129869

Dimensions Publication ID

30 September 2017

0 references

1 reference

PubMed ID

9129869